Alizé Pharma signs research collaboration and license option agreement with Lilly
Companies to collaborate on an exclusive basis on Alizé Pharma's unacylated ghrelin (AZP-01) program for the treatment of Type II diabetes
Alizé Pharma, a group of companies developing innovative therapeutics for metabolic diseases and cancer, announced that Alizé Pharma SAS has entered into a research collaboration and license option agreement with Eli Lilly and Company regarding Alizé Pharma's AZP-01 program, a program focused on the development of unacylated ghrelin (UAG) agonists for the treatment of type II diabetes.
Under the terms of the Agreement, Lilly will pay an undisclosed upfront fee and both companies will collaborate on Alizé's AZP-01 project. In return, Lilly will be granted an exclusive option to license the program according to predefined terms. Other terms of the deal were not disclosed.
Alizé's AZP-01 program aims at developing UAG agonists, a new potential therapeutic class for the treatment of Type II diabetes. Available preclinical and preliminary clinical data suggest that UAG and its analogs have a therapeutic potential in diabetes through a novel mechanism of action that includes glucose and lipid-lowering effects, a trophic effect on beta cells, as well as insulin-sensitizing actions. Thus, UAG and its analogs may have the potential not only to control the disease but also to have a positive impact on other cardiovascular risk factors such as obesity, dyslipidemia and impaired vascular remodeling.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
